Fulcrum Therapeutics, Inc.
FULC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680581
In the last 90 days, Fulcrum Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 154 institutions reported holding it in 13F filings for Q2 2026, worth $291.3M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Fulcrum Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 88 | 1 | 81 | −6 |
| Shares | 55.5M | 256.9K | 56.4M | +1.13M (+2.0%) |
| Value | $183.2M | $847.7K | $250.4M | +$68.0M (+37.3%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Fulcrum Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jefferies Financial Group Inc. | 1,433,316 | $6.36M | 0.16% |
| Jacobs Levy Equity Management, Inc | 265,506 | $1.18M | 0.01% |
| Alliancebernstein L.P. | 233,538 | $1.04M | 0.00% |
| Hudson Bay Capital Management LP | 196,488 | $872.4K | 0.01% |
| ClariVest Asset Management LLC | 104,400 | $464.0K | 0.03% |
| Jump Financial, LLC | 91,790 | $407.5K | 0.02% |
| Occudo Quantitative Strategies LP | 87,372 | $387.9K | 0.05% |
| Denali Advisors LLC | 70,600 | $313.5K | 0.11% |
| DekaBank Deutsche Girozentrale | 60,000 | $268.0K | 0.00% |
| Algert Global LLC | 31,010 | $137.7K | 0.01% |
| Landscape Capital Management, L.L.C. | 28,252 | $125.4K | 0.02% |
| Brown Wealth Management, LLC | 25,000 | $111.0K | 0.05% |
| Qube Research & Technologies Ltd | 13,066 | $58.0K | 0.00% |
| Centiva Capital, LP | 10,747 | $47.7K | 0.00% |
| Group One Trading, L.P. | 6,773 | $30.1K | 0.00% |
Sold out (21)
Institutions that held Fulcrum Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Point72 Asset Management, L.P. | 1,899,968 | $6.27M |
| Woodline Partners LP | 596,695 | $1.97M |
| Harvard Management Co Inc | 341,972 | $1.13M |
| Barclays PLC | 144,983 | $478.4K |
| Opaleye Management Inc. | 143,600 | $473.9K |
| State of Wisconsin Investment Board | 117,000 | $386.1K |
| Y-Intercept (Hong Kong) Ltd | 61,587 | $203.2K |
| Ergoteles LLC | 40,800 | $134.6K |
| Laurion Capital Management LP | 33,645 | $111.0K |
| Mirabella Financial Services LLP | 32,760 | $108.1K |
| Point72 Middle East FZE | 32,145 | $106.1K |
| Old Mission Capital LLC | 23,900 | $78.9K |
| Susquehanna Fundamental Investments, LLC | 22,594 | $74.6K |
| UBS Asset Management Americas Inc | 25,699 | $73.2K |
| Nantahala Capital Management, LLC | 21,370 | $70.5K |
| Quantamental Technologies LLC | 11,855 | $39.1K |
| Prelude Capital Management, LLC | 11,171 | $36.9K |
| Balyasny Asset Management LLC | 11,087 | $36.6K |
| DRW Securities, LLC | 11,000 | $36.0K |
| New York State Common Retirement Fund | 376 | $1.24K |
| NewSquare Capital LLC | 30 | $99 |
Not filed for Q3 2023 yet (1)
Institutions that held Fulcrum Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Tekla Capital Management LLC | 256,888 | $847.7K |